CA2998269C - Semifluorinated compounds for ophthalmic administration - Google Patents
Semifluorinated compounds for ophthalmic administration Download PDFInfo
- Publication number
- CA2998269C CA2998269C CA2998269A CA2998269A CA2998269C CA 2998269 C CA2998269 C CA 2998269C CA 2998269 A CA2998269 A CA 2998269A CA 2998269 A CA2998269 A CA 2998269A CA 2998269 C CA2998269 C CA 2998269C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- eye
- compound
- ophthalmic
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
- C07C17/263—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions
- C07C17/266—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions of hydrocarbons and halogenated hydrocarbons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C19/00—Acyclic saturated compounds containing halogen atoms
- C07C19/08—Acyclic saturated compounds containing halogen atoms containing fluorine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15187760 | 2015-09-30 | ||
| EP15187760.2 | 2015-09-30 | ||
| EP15192429.7 | 2015-10-30 | ||
| EP15192429 | 2015-10-30 | ||
| PCT/EP2016/073262 WO2017055453A1 (en) | 2015-09-30 | 2016-09-29 | Semifluorinated compounds for ophthalmic administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2998269A1 CA2998269A1 (en) | 2017-04-06 |
| CA2998269C true CA2998269C (en) | 2021-03-23 |
Family
ID=57068093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2998269A Active CA2998269C (en) | 2015-09-30 | 2016-09-29 | Semifluorinated compounds for ophthalmic administration |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11154513B2 (enExample) |
| EP (3) | EP3722274B1 (enExample) |
| JP (2) | JP6642935B2 (enExample) |
| KR (2) | KR102154415B1 (enExample) |
| CN (4) | CN113662929A (enExample) |
| AU (3) | AU2016329261B2 (enExample) |
| CA (1) | CA2998269C (enExample) |
| DE (1) | DE202016008739U1 (enExample) |
| DK (2) | DK3356313T3 (enExample) |
| ES (2) | ES2803248T3 (enExample) |
| MX (2) | MX391587B (enExample) |
| PL (2) | PL3356313T3 (enExample) |
| PT (1) | PT3356313T (enExample) |
| WO (1) | WO2017055453A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10045996B2 (en) | 2010-03-17 | 2018-08-14 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| EP2714010B1 (en) | 2011-05-25 | 2017-03-01 | Novaliq GmbH | Topical pharmaceutical composition based on semifluorinated alkanes |
| ES2625538T3 (es) | 2012-01-23 | 2017-07-19 | Novaliq Gmbh | Composiciones de proteínas estabilizadas basadas en alcanos semifluorados |
| BR112015005008B1 (pt) | 2012-09-12 | 2022-04-19 | Novaliq Gmbh | Composições de alcano semifluorado |
| CN104619314B (zh) | 2012-09-12 | 2017-09-22 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| CN114028560A (zh) | 2013-07-23 | 2022-02-11 | 诺瓦利克有限责任公司 | 稳定的抗体组合物 |
| CN108348777B (zh) | 2015-09-30 | 2020-04-28 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| CN113662929A (zh) * | 2015-09-30 | 2021-11-19 | 诺瓦利克有限责任公司 | 用于眼部给药的半氟化化合物 |
| USRE50060E1 (en) | 2016-06-23 | 2024-07-30 | Novaliq Gmbh | Topical administration method |
| ES2969758T3 (es) | 2016-09-22 | 2024-05-22 | Novaliq Gmbh | Composiciones farmacéuticas para usar en la terapia de la blefaritis |
| KR20190057338A (ko) | 2016-09-23 | 2019-05-28 | 노바리크 게엠베하 | 시클로스포린을 포함하는 안과 조성물 |
| ES2819005T3 (es) * | 2016-12-23 | 2021-04-14 | Novaliq Gmbh | Composición oftálmica para el tratamiento de la enfermedad del ojo seco |
| EP3612228B1 (en) | 2017-04-21 | 2023-08-23 | Dermaliq Therapeutics, Inc. | Iodine compositions |
| EP3619186B1 (en) | 2017-05-05 | 2021-02-17 | Novaliq GmbH | Process for the production of semifluorinated alkanes |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| MX2020003534A (es) | 2017-09-27 | 2020-07-29 | Novaliq Gmbh | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| AU2019228119A1 (en) | 2018-03-02 | 2020-09-10 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| IL276888B2 (en) | 2018-03-28 | 2024-12-01 | Novaliq Gmbh | Pharmaceutical composition comprising timolol |
| EP3784246A1 (en) | 2018-04-27 | 2021-03-03 | Novaliq GmbH | Ophthalmic compositions comprising tafluprost for the treatment of glaucoma |
| EP3856124A1 (en) | 2018-09-27 | 2021-08-04 | Novaliq GmbH | Lipid barrier repair |
| ES2950878T3 (es) | 2018-09-27 | 2023-10-16 | Dermaliq Therapeutics Inc | Formulación de protección solar de uso tópico |
| CN112823020A (zh) | 2018-10-12 | 2021-05-18 | 诺瓦利克有限责任公司 | 用于治疗干眼病的眼用组合物 |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| AU2020340561B2 (en) | 2019-09-06 | 2026-01-22 | Novaliq Gmbh | Ophthalmic composition for the treatment of uveitis |
| CA3233317A1 (en) * | 2024-03-26 | 2025-10-30 | Apotex Inc. | Solid complexes comprising urea and semifluorinated alkanes |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2616927A (en) | 1950-05-12 | 1952-11-04 | Minnesota Mining & Mfg | Fluorocarbon tertiary amines |
| US4452818A (en) | 1982-03-19 | 1984-06-05 | Haidt Sterling J | Extraocular method of treating the eye with liquid perfluorocarbons |
| US5077036A (en) | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
| JPS6452722A (en) | 1987-05-01 | 1989-02-28 | Anjierini Pharmaceut Inc | Ophthalmic composition |
| US6458376B1 (en) | 1990-09-27 | 2002-10-01 | Allergan, Inc. | Nonaqueous fluorinated drug delivery suspensions |
| US5518731A (en) | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
| US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| GB9114374D0 (en) | 1991-07-03 | 1991-08-21 | Smithkline Beecham Plc | Novel process |
| FR2679150A1 (fr) | 1991-07-17 | 1993-01-22 | Atta | Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations. |
| US6602900B2 (en) | 1992-09-21 | 2003-08-05 | Allergan, Inc. | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5336175A (en) | 1992-10-29 | 1994-08-09 | Mames Robert N | Method for the treatment of retinal detachments |
| US5370313A (en) | 1994-01-10 | 1994-12-06 | Beard; Walter C. | Sterile liquid dispenser |
| DE4405627A1 (de) | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
| FR2720943B1 (fr) | 1994-06-09 | 1996-08-23 | Applic Transferts Technolo | Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples. |
| US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
| US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
| US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
| US5874481A (en) | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
| DE19536504C2 (de) * | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| US5874469A (en) | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
| FR2752161B1 (fr) | 1996-08-07 | 1998-09-25 | Atta | Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles |
| US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
| IN184589B (enExample) | 1996-10-16 | 2000-09-09 | Alza Corp | |
| DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
| US5980936A (en) | 1997-08-07 | 1999-11-09 | Alliance Pharmaceutical Corp. | Multiple emulsions comprising a hydrophobic continuous phase |
| US5981607A (en) | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
| BR9904780A (pt) | 1998-02-09 | 2000-03-08 | Macrochem Corp | Esmalte fungicida para unhas e método de uso do mesmo |
| DE19861012A1 (de) | 1998-03-18 | 1999-09-30 | Pharm Pur Gmbh | Behandlungsmittel für die Ophthalmologie |
| JP4198318B2 (ja) | 1998-08-19 | 2008-12-17 | ヤーゴテック アクチェンゲゼルシャフト | プロポフォールの注射可能水性分散物 |
| US6140374A (en) | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
| US6159977A (en) | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
| US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
| KR20080045300A (ko) | 1999-02-08 | 2008-05-22 | 알자 코포레이션 | 안정한 비수성 단일상 점성 비히클 및 그 비히클을이용하는 제형물 |
| AU3898700A (en) | 1999-03-15 | 2000-10-04 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
| US6177477B1 (en) | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| DE19926890C1 (de) | 1999-06-12 | 2000-07-27 | Pharm Pur Gmbh | Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie |
| DE19938668B4 (de) | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
| US6528086B2 (en) | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
| JP2001158734A (ja) | 1999-12-02 | 2001-06-12 | Lion Corp | 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法 |
| US20030018044A1 (en) | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
| DE10024413A1 (de) | 2000-05-19 | 2001-12-06 | Mika Pharma Gmbh | Pharmazeutische und/oder kosmetische Zubereitung |
| WO2005039531A1 (en) | 2003-10-10 | 2005-05-06 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
| WO2002089849A1 (en) | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
| DE60223694T2 (de) | 2001-09-04 | 2008-10-30 | Trommsdorff Gmbh & Co. Kg Arzneimittel | Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US7074827B2 (en) | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
| CA2536482C (en) | 2003-08-25 | 2012-07-24 | Foamix Ltd. | Penetrating pharmaceutical foam |
| US20050079210A1 (en) | 2003-10-09 | 2005-04-14 | Gupta Shyam K. | Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients |
| CA2540621A1 (en) | 2003-11-19 | 2005-06-09 | Barnes-Jewish Hospital | Enhanced drug delivery |
| GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| ES2387619T3 (es) | 2004-04-19 | 2012-09-27 | Centre National De La Recherche Scientifique (Cnrs) | Suplementos de tensioactivos pulmonares |
| JP2008501806A (ja) | 2004-06-08 | 2008-01-24 | オキュラリス ファーマ， インコーポレイテッド | 疎水性眼用組成物および使用方法 |
| US7063241B2 (en) | 2004-06-10 | 2006-06-20 | Allergan, Inc. | Dispensing tip |
| CN101043884A (zh) | 2004-07-01 | 2007-09-26 | 谢彭斯眼科研究公司 | 用于治疗眼部疾病和病症的组合物和方法 |
| US7740875B2 (en) | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| EP1688161A1 (en) | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| US7851504B2 (en) | 2005-03-16 | 2010-12-14 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
| GB0511499D0 (en) | 2005-06-06 | 2005-07-13 | Medpharm Ltd | Topical ungual formulations |
| EP1922060B1 (en) | 2005-08-05 | 2009-01-14 | Bharat Serums & Vaccines Ltd. | Intravenous propofol emulsion compositions having preservative efficacy |
| FR2892023B1 (fr) | 2005-10-14 | 2009-09-25 | Galderma Sa | Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale |
| DE102005055811A1 (de) * | 2005-11-23 | 2007-05-31 | Novaliq Gmbh | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
| TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| AR062046A1 (es) | 2006-07-25 | 2008-08-10 | Osmotica Pharmaceutical Argentina S A | Soluciones oftalmicas |
| EP2046290A4 (en) | 2006-08-04 | 2011-08-17 | Insys Therapeutics Inc | AQUEOUS DRONABINOL FORMULATIONS |
| JP5694664B2 (ja) | 2006-09-29 | 2015-04-01 | サーモディクス，インコーポレイティド | 生分解性眼用インプラント及び眼の病気を治療する方法 |
| US9000048B2 (en) | 2006-11-28 | 2015-04-07 | Wisconsin Alumni Research Foundation | Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics |
| EP2089282B1 (en) | 2006-12-07 | 2014-01-08 | Sun Pharma Advanced Research Company Ltd | Metered drop bottle for dispensing microliter amounts of a liquid in the form of a drop |
| CN200977281Y (zh) | 2006-12-08 | 2007-11-21 | 陈宇 | 带助滴器的滴眼瓶 |
| FR2918891B1 (fr) | 2007-07-20 | 2009-09-25 | Thea Sa Lab | Solution ophtalmique a base de prostaglandines sans conservateur |
| US8222292B2 (en) | 2007-08-06 | 2012-07-17 | Insys Therapeutics, Inc. | Liquid cannabinoid formulations |
| DE102007055046A1 (de) | 2007-11-19 | 2009-05-28 | Fluoron Gmbh | Infusionslösung |
| EP2110126B9 (de) | 2008-04-18 | 2012-09-19 | Novaliq GmbH | Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich |
| US20100006600A1 (en) | 2008-07-14 | 2010-01-14 | Dascanio Gustavo A | Fluid dispenser including hydrophobic ring |
| PL2352497T3 (pl) | 2008-10-31 | 2017-08-31 | University Of Mississippi | Proces przygotowania estrów aminokwasowych delta-9-thc |
| JP2012509737A (ja) | 2008-11-26 | 2012-04-26 | サーモディクス，インコーポレイティド | 埋め込み式の眼薬送達器具および眼薬送達方法 |
| US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
| IT1393419B1 (it) | 2009-03-19 | 2012-04-20 | Medivis S R L | Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6. |
| WO2010146536A1 (en) | 2009-06-18 | 2010-12-23 | Koninklijke Philips Electronics N.V. | Suspension of particles with drug |
| JP5736635B2 (ja) | 2009-06-25 | 2015-06-17 | ライオン株式会社 | ドライアイ治療剤 |
| WO2010150378A1 (ja) | 2009-06-25 | 2010-12-29 | ライオン株式会社 | 眼科用組成物 |
| EP2387391B1 (de) | 2009-07-24 | 2017-01-11 | MIKA Pharma Gesellschaft für die Entwicklung und Vermarktung pharmazeutischer Produkte mbH | Verfahren zur entwicklung einer als schaum auf die haut zu applizierenden flüssigen zusammensetzung sowie eine topisch applizierbare zusammensetzung |
| JP2011024841A (ja) | 2009-07-28 | 2011-02-10 | 健太 ▲浜崎▼ | 点眼補助具 |
| EP2332525A1 (en) | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmaceutical composition comprising propofol |
| EP2335735A1 (en) | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| US10045996B2 (en) | 2010-03-17 | 2018-08-14 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| DE102010022567A1 (de) * | 2010-06-02 | 2011-12-08 | Fluoron Gmbh | Zubereitung |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) * | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| KR101910213B1 (ko) | 2011-01-04 | 2018-12-19 | 노바리크 게엠베하 | 부분불소화된 알칸을 포함하는 수중유형 에멀젼 |
| DK2714008T3 (en) | 2011-05-25 | 2017-03-13 | Novaliq Gmbh | PHARMACEUTICAL COMPOSITION FOR APPLICATION ON NAIL |
| EP2714010B1 (en) | 2011-05-25 | 2017-03-01 | Novaliq GmbH | Topical pharmaceutical composition based on semifluorinated alkanes |
| CN202136470U (zh) | 2011-06-08 | 2012-02-08 | 天津市金亿达药用包装材料有限公司 | 便于滴药的眼药瓶 |
| US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
| ES2625538T3 (es) | 2012-01-23 | 2017-07-19 | Novaliq Gmbh | Composiciones de proteínas estabilizadas basadas en alcanos semifluorados |
| WO2013126602A1 (en) | 2012-02-21 | 2013-08-29 | Massachusetts Eye & Ear Infirmary | Inflammatory eye disorders |
| US9878000B2 (en) | 2012-06-20 | 2018-01-30 | University Of Waterloo | Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof |
| CN104619314B (zh) | 2012-09-12 | 2017-09-22 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| BR112015005008B1 (pt) * | 2012-09-12 | 2022-04-19 | Novaliq Gmbh | Composições de alcano semifluorado |
| EP2730291A1 (en) * | 2012-11-09 | 2014-05-14 | Fluoron Gmbh | Internal Tamponade Composition |
| EP2783703A1 (en) | 2013-03-25 | 2014-10-01 | B. Braun Melsungen AG | Semifluorocarbon compound containing contrast agent |
| CN114028560A (zh) | 2013-07-23 | 2022-02-11 | 诺瓦利克有限责任公司 | 稳定的抗体组合物 |
| US9265809B2 (en) | 2013-10-09 | 2016-02-23 | Johnson Living Trust dated October 26, 2011, Leonidas A. Johnson, Trustee | Methods and compositions for treating and preventing signs or symptoms of eye disease |
| CN203524843U (zh) | 2013-10-20 | 2014-04-09 | 吕相瑜 | 自助滴眼液辅助支架 |
| ES2784229T3 (es) | 2013-11-20 | 2020-09-23 | Panag Pharma Inc | Composiciones y procedimientos para el tratamiento de la inflamación y el dolor ocular |
| CA2943255C (en) | 2014-03-31 | 2023-01-24 | Amcor Limited | Controlled release container |
| EP2944324A1 (de) | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
| CA2955964C (en) | 2014-08-13 | 2024-05-07 | University Of Florida Research Foundation, Inc. | Preservative removal from eye drops |
| MA41299A (fr) | 2014-12-30 | 2017-11-07 | Axim Biotechnologies Inc | Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite |
| CN113662929A (zh) * | 2015-09-30 | 2021-11-19 | 诺瓦利克有限责任公司 | 用于眼部给药的半氟化化合物 |
| CN108348777B (zh) * | 2015-09-30 | 2020-04-28 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| USRE50060E1 (en) | 2016-06-23 | 2024-07-30 | Novaliq Gmbh | Topical administration method |
| ES2969758T3 (es) | 2016-09-22 | 2024-05-22 | Novaliq Gmbh | Composiciones farmacéuticas para usar en la terapia de la blefaritis |
| KR20190057338A (ko) | 2016-09-23 | 2019-05-28 | 노바리크 게엠베하 | 시클로스포린을 포함하는 안과 조성물 |
| BR112019006194A2 (pt) | 2016-09-28 | 2019-06-18 | Novaliq Gmbh | composições que compreendem um ligante de ligação ao receptor de canabinóides |
| WO2018114557A1 (en) | 2016-12-22 | 2018-06-28 | Novaliq Gmbh | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases |
| ES2819005T3 (es) | 2016-12-23 | 2021-04-14 | Novaliq Gmbh | Composición oftálmica para el tratamiento de la enfermedad del ojo seco |
-
2016
- 2016-09-29 CN CN202110943867.0A patent/CN113662929A/zh active Pending
- 2016-09-29 JP JP2018515471A patent/JP6642935B2/ja active Active
- 2016-09-29 CN CN202110942390.4A patent/CN113662928B/zh active Active
- 2016-09-29 DK DK16775673.3T patent/DK3356313T3/da active
- 2016-09-29 PL PL16775673T patent/PL3356313T3/pl unknown
- 2016-09-29 AU AU2016329261A patent/AU2016329261B2/en active Active
- 2016-09-29 EP EP20172665.0A patent/EP3722274B1/en active Active
- 2016-09-29 PT PT167756733T patent/PT3356313T/pt unknown
- 2016-09-29 EP EP23176082.8A patent/EP4234523A1/en active Pending
- 2016-09-29 PL PL20172665.0T patent/PL3722274T3/pl unknown
- 2016-09-29 ES ES16775673T patent/ES2803248T3/es active Active
- 2016-09-29 WO PCT/EP2016/073262 patent/WO2017055453A1/en not_active Ceased
- 2016-09-29 US US15/280,411 patent/US11154513B2/en active Active
- 2016-09-29 MX MX2020001408A patent/MX391587B/es unknown
- 2016-09-29 EP EP16775673.3A patent/EP3356313B1/en active Active
- 2016-09-29 ES ES20172665T patent/ES2953837T3/es active Active
- 2016-09-29 CA CA2998269A patent/CA2998269C/en active Active
- 2016-09-29 KR KR1020187010285A patent/KR102154415B1/ko active Active
- 2016-09-29 MX MX2018003781A patent/MX2018003781A/es active IP Right Grant
- 2016-09-29 CN CN201911100909.3A patent/CN110693825B/zh active Active
- 2016-09-29 CN CN201680056178.5A patent/CN108349855B/zh active Active
- 2016-09-29 KR KR1020207025363A patent/KR102584063B1/ko active Active
- 2016-09-29 DK DK20172665.0T patent/DK3722274T3/da active
- 2016-09-29 DE DE202016008739.9U patent/DE202016008739U1/de active Active
-
2019
- 2019-12-30 JP JP2019240070A patent/JP7050741B2/ja active Active
-
2020
- 2020-07-14 AU AU2020205239A patent/AU2020205239B9/en active Active
-
2021
- 2021-06-17 US US17/350,427 patent/US20210315832A1/en active Pending
-
2022
- 2022-01-20 AU AU2022200366A patent/AU2022200366B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022200366B2 (en) | Semifluorinated compounds for ophthalmic administration | |
| US12128010B2 (en) | Semifluorinated compounds and their compositions | |
| HK1257183A1 (en) | Semifluorinated compounds and their compositions | |
| HK40099432A (en) | Semifluorinated compounds for ophthalmic administration | |
| HK40039482B (en) | 2-perfluorobutyl pentane for ophthalmic administration | |
| HK40039482A (en) | 2-perfluorobutyl pentane for ophthalmic administration | |
| HK40006723B (en) | Semifluorinated compounds and their compositions | |
| HK40006723A (en) | Semifluorinated compounds and their compositions | |
| HK1257182B (en) | 2-perfluorohexyl octane for ophthalmic administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200109 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250313 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250313 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250915 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250915 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251210 |